Mirae Asset Healthcare Fund
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India.
Growthvine rating: 4/5 — ranked #14 of 84 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹45.26 (as of 2026-08-21) |
|---|
| AUM | ₹3,253 Cr |
|---|
| Expense ratio | 1.65% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Tanmay Mehta |
|---|
| Exit load | 1% for redemption within 1 month |
|---|
Performance & risk
| 5-year annualised return | 14.36% |
|---|
| Sharpe ratio | 0.96 |
|---|
| Standard deviation | 16.11% |
|---|
| Max drawdown | -20.09% |
|---|
| Alpha | -0.74 |
|---|
| Beta | 0.97 |
|---|
Over 5 years, captured 94.5% of NIFTY Pharma's upside and 90.0% of its downside.
Market cap allocation
| Large cap | 36.7% |
|---|
| Mid cap | 44.4% |
|---|
| Small cap | 18.9% |
|---|
Concentration
| Top 5 holdings | 38.7% |
|---|
| Top 10 holdings | 58.3% |
|---|
| Total holdings | 27 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 11.1%
- Divis Laboratories Ltd. — 8.7%
- Torrent Pharmaceuticals Ltd. — 7.5%
- Apollo Hospitals Enterprises Ltd. — 5.9%
- Glenmark Pharmaceuticals ltd — 5.5%
- Laurus Labs Limited — 5.1%
- Aurobindo Pharma Ltd. — 3.8%
- Alkem Laboratories Limited — 3.6%
- Fortis Healthcare Ltd — 3.5%
- Krishna Institute of Medical Sciences Limited — 3.5%
Top sectors
- Pharma & Biotech — 74.8%
- Healthcare — 22.9%
- Chemicals — 1.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 18.5% | Q1 (Top) | #10 of 76 |
| 2025 | -3.4% | Q3 | #47 of 69 |
| 2024 | 39.1% | Q1 (Top) | #12 of 58 |
| 2023 | 34.0% | Q3 | #29 of 48 |
| 2022 | -11.8% | Q4 (Bottom) | #39 of 46 |